Euroasian Journal of Hepato-Gastroenterology

Register      Login

VOLUME 7 , ISSUE 2 ( July-December, 2017 ) > List of Articles

RESEARCH ARTICLE

Hemochromatosis Gene Polymorphism as a Predictor of Sustained Virological Response to Antiviral Treatment in Egyptian Chronic Hepatitis C Patients

Mai I Mehrez, Dina SA Fattah, Naglaa AA Azeem, Mohamed A Saleh, Khadiga M Mostafa

Citation Information : Mehrez MI, Fattah DS, Azeem NA, Saleh MA, Mostafa KM. Hemochromatosis Gene Polymorphism as a Predictor of Sustained Virological Response to Antiviral Treatment in Egyptian Chronic Hepatitis C Patients. Euroasian J Hepatogastroenterol 2017; 7 (2):154-157.

DOI: 10.5005/jp-journals-10018-1238

License: CC BY 3.0

Published Online: 01-12-2017

Copyright Statement:  Copyright © 2017; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Aim

The aim of this article is to assess HFE C282Y gene mutations as a predictor of sustained virological response (SVR) to anti-hepatitis C virus (HCV) treatment in Egyptian patients.

Materials and methods

One hundred and forty chronic hepatitis C (CHC) patients were divided into two groups: 70 patients achieved SVR and 70 patients were nonresponders (NRs). All patients were subjected to quantitative polymerase chain reaction (PCR) at baseline, 12 and 24 weeks after therapy commencement. Deoxyribonucleic acid (DNA) sequencing for HFE (C282Y) was done by restriction fragment length polymorphism PCR.

Results

Sixty five patients did not have mutation and 5 patients had C282Y mutation (GA) with SVR. While 45 NRs had heterozygous C282Y mutation (GA), 4 patients (5.7%) had homozygous mutation (AA) and 21 patients (30%) had no mutation (GG). The parameters of elevated iron [transferrin saturation (TS; p < 0.001), S iron (p < 0.02), total iron binding capacity (TIBC; p < 0.001), transferrin (p < 0.016), and soluble transferrin receptor (sTfR; p-value, 0.001)] were significantly associated with C282Y mutation. However, there was no significant difference regarding ferritin values and C282Y mutation in NR patients.

Conclusion

Iron overload was frequently detected in CHC patients and associated with C282Y mutation, while biochemical markers of iron overload and C282Y HFE mutation were negative prognostic factor.

How to cite this article

Mehrez MI, Fattah DSA, Azeem NAA, Saleh MA, Mostafa KM. Hemochromatosis Gene Polymorphism as a Predictor of Sustained Virological Response to Antiviral Treatment in Egyptian Chronic Hepatitis C Patients. Euroasian J Hepato-Gastroenterol 2017;7(2):154-157.


  1. Chronic hepatitis C and genotyping. The clinical significance of determining HCV genotypes. Antivir Ther 2005 Jan;10(1):1-11.
  2. Epidemiology of HCV in Egypt 2004. Afro Arab Liver J 2004;l3(2):41-52.
  3. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol 2004 Jan;44(1):20-29.
  4. Elevated hepatic iron: a confounding factor in chronic hepatitis C. Biochim Biophys Acta 2009 Jul;1790(7):650-662.
  5. Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C. Gastroenterology 2006 Nov;131(5):1440-1451.
  6. Hepatic iron concentration does not predict response to standard and pegylated-IFN/ribavirin therapy in patients with chronic hepatitis C. J Hepatol 2004 Jun;40(6):1018-1022.
  7. Iron and HFE or TfR1 mutations as comorbid factors for development and progression of chronic hepatitis C. J Hepatol 2002 Dec;37(6):848-854.
  8. Serum ferritin as a predictor of treatment outcome in patients with chronic hepatitis C. Am J Gastroenterol 2009 Mar;104(3):605-616.
  9. Geography of HFE C282Y and H63D mutations. Genet Test 2000 Feb;4(2):183-198.
  10. Hepatitis C, iron status, and disease severity: relationship with HFE mutations. Gastroenterology 2003 Feb;124(2):318-326.
  11. Liver damage in Italian patients with hereditary hemochromatosis is highly influenced by hepatitis B and C virus infection. J Hepatol 1992 Nov;16(3):364-368.
  12. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multicenter, prospective, randomized, controlled trial. Hepatology 2000 Jul;32(1):135-138.
  13. Hemochromatosis gene mutations: prevalence and effects on pegylated-interferon and ribavirin therapy response in chronic hepatitis C in Sardinia. J Clin Exp Hepatol 2012 Sep;2(3):211-217.
  14. HFE mutations prevent sustained virological response to interferon plus ribavirin in chronic hepatitis C patients with serum markers of iron overload. Am J Gastroenterol 2002 Jun;97(6):1570-1572.
  15. The H63D mutation of the hemochromatosis gene is associated with sustained virological response in chronic hepatitis C patient treated with interferon based therapy: a meta analysis. Tohoku J Exp Med 2012 Apr;226(4):293-299.
  16. Influence of HFE gene polymorphism on the progression and treatment of chronic hepatitis C. J Viral Hepat 2004 Mar;11(2):175-182.
  17. Iron enhances hepatitis C virus replication in cultured human hepatocytes. Liver 2000 Apr;20(2):125-128.
  18. Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease. Hepatology 2001 Mar;33(3):647-651.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.